Key Takeaways Insulet shares tumbled Friday after the maker of insulin management devices suggested new user growth could be lower than previously expected in the second half of 2024. Strong sales of its Omnipod device helped Insulet top second-quarter revenue expectations. The company raised its guidance for full-year revenue growth. Shares of Insulet (PODD) suffered the heaviest losses of any S&P 500 stock on Friday, dropping 8.8% after the maker of insulin management devices suggested new user growth cou ...

Insulet Corporation (PODD) reported second-quarter 2024 adjusted earnings per share (EPS) of 55 cents, up significantly 44.7% from the year-ago period's figure. The bottom line missed the Zacks Consensus Estimate by 3.5%. GAAP EPS was $2.59 compared with the year-ago figure of 39 cents. Q2 Revenues Revenues totaled $488.5 million, which beat the Zacks Consensus Estimate by 5.5%. The top line jumped 23.2% year over year (up 23.4% at the constant exchange rate or CER). CER growth exceeded the company's guidan ...

| --- | --- | --- | --- | --- | |------------------|-------|-------------------|-------|-------| | | | | | | | | | Mattie | | | | | | Podder since 2010 | | | | | | | | | | | | | | | | Insulet | | | | | | Corporation | | | | | | Q2'24 Earnings | | | | | | August 8, 2024 | | | | | This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials and the approval of products by regulat ...

Financial Performance - In Q2 2024, Insulet achieved total Omnipod revenue growth of 26%, with U.S. growth at 27% and international growth at 24% [6][24] - The company raised its full-year guidance for revenue, gross margin, and operating margin due to strong first-half results and momentum [6][31] - Gross margin was reported at 67.7%, up 90 basis points year-over-year, driven by pricing benefits and manufacturing efficiencies, despite a one-time charge of $13.5 million impacting margins [28][29] Business Line Performance - Omnipod 5 continues to drive growth, with approximately 85% of new U.S. customer starts coming from patients previously using multiple daily injections (MDI) [7][42] - The company is expanding its product offerings, including the integration of Omnipod 5 with Dexcom's G7 and Abbott's Freestyle Libre 2 Plus sensors, which is expected to enhance customer experience and drive demand [10][13] - The type 2 diabetes segment represented roughly 25% of U.S. new customer starts, indicating a strong ongoing trend in this underpenetrated market [16][19] Market Performance - Internationally, Insulet is approaching $0.5 billion in annual revenue for 2024, with growth rates above 20% expected [9][34] - The company has launched Omnipod 5 in France and is preparing for additional launches in Italy, Canada, and other markets, indicating significant international growth potential [15][34] - The demand for Omnipod 5 is strong in the UK and Germany, with early positive feedback from the recent launch in France [58] Company Strategy and Industry Competition - Insulet's strategy focuses on transitioning patients from MDI to Omnipod therapy, which has resulted in a rapidly increasing customer base [7][21] - The company aims to capture the type 2 diabetes market by leveraging its existing technology and expanding its sales force in anticipation of FDA clearance for Omnipod 5's label expansion [19][22] - Insulet is positioned as a leader in automated insulin delivery, with a clear competitive advantage in the pharmacy channel [8][21] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in achieving robust revenue growth and margin expansion in the second half of 2024, driven by strong demand for Omnipod 5 and ongoing product innovations [5][31] - The company anticipates a less steep ramp in new customer starts in the second half of 2024 due to market dynamics and inventory management strategies [33][52] - Insulet expects to maintain a strong growth trajectory, with guidance for total Omnipod revenue growth raised to a range of 18% to 21% for the full year [31][32] Other Important Information - The company ended the quarter with approximately $820 million in cash and successfully extended the maturity of its Term Loan B to August 2031 [31] - Insulet's new manufacturing facility in Malaysia is expected to enhance production capacity and contribute positively to gross margins [23][36] Q&A Session Summary Question: Clarification on gross margin and operating margin - The question addressed the impact of a one-time charge on gross margin and why it was not backed out [39] Answer: Management clarified that they do not adjust for operational items and provided details on the impact of the charge [40][43] Question: Inquiry about new customer starts in Q3 and Q4 - A question was raised regarding the expected growth in new customer starts for the second half of the year [44] Answer: Management confirmed sequential growth in new customer starts in both the U.S. and internationally [45][50] Question: Clarification on competitive converts and market dynamics - A question was posed about the shift in competitive converts and its implications for market strategy [56] Answer: Management explained that the focus remains on MDI growth, with competitive switching being a smaller part of the overall strategy [59][60]

Insulet (PODD) reported $488.5 million in revenue for the quarter ended June 2024, representing a year-overyear increase of 23.2%. EPS of $0.55 for the same period compares to $0.38 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $463.13 million, representing a surprise of +5.48%. The company delivered an EPS surprise of -3.51%, with the consensus EPS estimate being $0.57. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stree ...

Insulet (PODD) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -3.51%. A quarter ago, it was expected that this maker of insulin infusion systems would post earnings of $0.39 per share when it actually produced earnings of $0.73, delivering a surprise of 87.18%. Over the last four qua ...

Table of Contents _____________________________________________________ ________________________________________________________________________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q _____________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SE ...

Exhibit 99.1 Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year Raising Full Year Revenue, Gross Margin and Operating Margin Guidance ACTON, Mass. - August 8, 2024 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced financial results for the three months ended June 30, 2024. ® Second Quarter Financial Highlights: 1 • Second quarter 2024 revenue of $488.5 million, up 23 ...

Insulet (PODD) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. Therefore, the Zacks rating upgrade for Insulet basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. Fundamentally speaking, rising earnings estimates and the consequent rating upgrade f ...

Timothy Scannell, former President and Chief Operating Officer of Stryker Located in Massachusetts' healthcare hub, CereVasc, Inc., is a clinical stage, medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases. Its initial product, the eShunt System, encompasses first-ever, groundbreaking percutaneous transvenous-transdural access to the central nervous system intended to allow the first minimally invasive treatment for communicating h ...